Vertex CF Drugs - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

BioPharma Dive · 18h

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

The Patriot Ledger · 2h

FDA approves first new non-opioid painkiller in decades, and it's from a MA company.

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday. The drug, which is called suzetrigine and will be sold under the brand name Journavx, is the first new type of pain medicine approved by the agency in more than 20 years.

The Associated Press on MSN · 3h

FDA Approves Painkiller Meant To Eliminate The Risk Of Opioid Addiction

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.

21hon MSN

Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Cargo to lay off staff after CAR-T data show safety concerns

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AFP10h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

7d

2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

5don MSN

Is Vertex Pharmaceuticals Stock a Buy in 2025?

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

BioPharma Dive10d

Sionna, Odyssey join queue of biotechs testing investors’ IPO interest

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

6h

Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results